ArticleScience advances2020
RACK7 recognizes H3.3G34R mutation to suppress expression of MHC class II complex components and their delivery pathway in pediatric glioblastoma.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Forebrain Lineage Factor DMRTA2 Is Not Required for Maintenance of H3G34-Mutant Paediatric High-Grade Gliomas.Journal of cellular and molecular medicine · 2026Article
- CBFA2T2: a novel H3K27 reader regulating metabolism and tumor growth.Molecular cancer · 2026Article
- G34R cancer mutation alters the conformational ensemble and dynamics of the histone H3.3 tails.Nucleic acids research · 2026Article
- Implications of canonical histone H3.1 and histone variant H3.3 in cancer.Open biology · 2025Review
- Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.Acta neuropathologica communications · 2025Review
- RACK7 Interacts with PRC2 Complex to Regulate Astrocyte Development.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2.The Journal of clinical investigation · 2024Article
- Review
- Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Impact of epigenetic reprogramming on antitumor immune responses in glioma.The Journal of clinical investigation · 2023Review
- Histone Readers and Their Roles in Cancer.Cancer treatment and research · 2023Article
- Glioblastoma-derived extracellular vesicle subpopulations following 5-aminolevulinic acid treatment bear diagnostic implications.Journal of extracellular vesicles · 2022Article
- ARID1A-dependent maintenance of H3.3 is required for repressive CHD4-ZMYND8 chromatin interactions at super-enhancers.BMC biology · 2022Article
- ZMYND8 is a master regulator of 27-hydroxycholesterol that promotes tumorigenicity of breast cancer stem cells.Science advances · 2022Article
- Oncohistones: Hijacking the histone code.Annual review of cancer biology · 2022Article
- Oncohistones: a roadmap to stalled development.The FEBS journal · 2022Review
- Chromatin mutations in pediatric high grade gliomas.Frontiers in oncology · 2022Review
- Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas.Science translational medicine · 2021Article
- The language of chromatin modification in human cancers.Nature reviews. Cancer · 2021Review
- ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 8 institutions in 4 countries.
Fangfang JiaoCenter for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, and the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.ORCID 0000-0002-7377-1151
Ze LiFudan University Shanghai Cancer Center, Institute of Biomedical Sciences, State Key Laboratory of Genetic Engineering and Shanghai Key Laboratory of Medical Epigenetics, Shanghai Medical College of Fudan University, Shanghai 200032, China.ORCID 0000-0003-4179-8672
Chen HeDepartment of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0003-1452-8511
Wenqi XuCenter for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, and the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.
Gensheng YangCenter for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, and the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.
Tingting LiuState Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science and Institutes of Brain Science, Fudan University, Shanghai 200032, China.
Hongjie ShenCenter for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, and the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.
Jiajun CaiDepartments of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
Jamie N AnastasNewborn Medicine Division, Boston Children's Hospital and Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Ying MaoDepartments of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
Yongchun YuState Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science and Institutes of Brain Science, Fudan University, Shanghai 200032, China.ORCID 0000-0002-7456-7451
Fei LanShanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yujiang Geno ShiDivision of Endocrinology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-9490-7081
Chris JonesDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.ORCID 0000-0001-8118-2296
Yanhui XuFudan University Shanghai Cancer Center, Institute of Biomedical Sciences, State Key Laboratory of Genetic Engineering and Shanghai Key Laboratory of Medical Epigenetics, Shanghai Medical College of Fudan University, Shanghai 200032, China.ORCID 0000-0002-1408-5178
Suzanne J BakerDepartment of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0002-5833-472X
Yang ShiNewborn Medicine Division, Boston Children's Hospital and Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-9713-1709
Rui GuoCenter for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, and the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.ORCID 0000-0002-1548-7582
Shanghai Medical College of Fudan University · CNBrigham and Women's Hospital · USFudan University · CNHuashan Hospital · CNSt. Jude Children's Research Hospital · USBoston Children's Hospital · USInstitute of Cancer Research · GBMinistry of Science and Technology · LA
Funding
The DNA Damage Response and Tumorigenesis in the BrainP01CA096832 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, SUZANNE J. · 2003 to 2025
$38.0MEpigenetic regulation of cellular plasticity and cancer cell fateR35CA210104 · NCI · BOSTON CHILDREN'S HOSPITAL · PI SHI, YANG · 2017 to 2019
$2.8MNCI NIH HHS P01 CA096832NCI NIH HHS R35 CA210104
Abstract
Histone H3 point mutations have been identified in incurable pediatric brain cancers, but the mechanisms through which these mutations drive tumorigenesis are incompletely understood. Here, we provide evidence that RACK7 (ZMYND8) recognizes the histone H3.3 patient mutation (H3.3G34R) in vitro and in vivo. We show that RACK7 binding to H3.3G34R suppresses transcription of
Indexed as
Brain NeoplasmsGlioblastomaHistocompatibility Antigens Class IIHistonesTumor Suppressor ProteinsChildHumansMutationHistocompatibility Antigens Class IIHistonesTumor Suppressor ProteinsZMYND8 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.